Sign in
Taking peoplePhase 4

ILUVIEN eye implant for children with recurring uveitis at the back of the eye

Tests the ILUVIEN eye implant in children with recurring non-infectious posterior uveitis.

Key facts

Who runs it
Alimera Sciences Europe Limited
Where
Germany and Spain4 sites in 2 countriesChoose a country to see its sites
Registry title
A Multicentre Study to Evaluate the Safety and Efficacy of the Eye Implant ILUVIEN® in Children with non-infectious uveitis affecting the posterior segment of the eye
Status
Recruiting
Phase
Phase 4
People taking part
10 people, planned
Started
17 Apr 2024
Expected to end
1 Dec 2027
Type of study
Interventional
Record updated
30 April 2026

Who can take part

The trial is looking for children and teenagers with non-infectious uveitis (eye inflammation not caused by infection) in the back part of the eye that keeps coming back. They will receive the ILUVIEN® eye implant.

Age
6 to less than 18 years
Sex
Boys and girls
Disease stage
Non-infectious uveitis in the back part of the study eye, coming back at least 1 time per year. Standard care did not control it well, because of poor response or side effects that could not be tolerated. There must be active inflammation (anterior chamber cells or vitreous haze of at least Grade 1) or swelling of the macula. Vision in the study eye must be at least 35 letters on the ETDRS chart.
Earlier treatment
Must have had systemic corticosteroids or other systemic therapy for at least 3 months within the 12 months before Day 1. Cannot have had Ozurdex in the eye within 6 months, or a fluocinolone eye implant in the study eye within 3 years.
Main reasons for not taking part
  • Uveitis caused by infection, or eye inflammation from another condition such as eye lymphoma
  • Any glaucoma or high eye pressure in the study eye, unless treated by surgery at least 90 days before with stable pressure
  • Eye surgery in the study eye within 90 days, or eye cancer in either eye
  • Corrected vision below 20/200 in the study eye
  • Pregnant or breastfeeding, or unwilling to use contraception
Show the full registry criteria (44)Hide the full registry criteria

Who can take part

  • Males and females of ≥6 and <18 years of age at time of consent
  • Subject is not planning to undergo elective ocular surgery during the trial
  • Presence of a signed written informed consent form from the subject or subject's legal representative, and/or a signed info assent from subject in accordance with local legal requirements
  • Non-infectious uveitis affecting the posterior segment of the study eye with a history of recurrence ≥1 per year as assessed by the Investigator
  • Uveitis in the study eye not adequately controlled by the preferred standard of care due to intolerable adverse effects or poor response, in the judgment of the Investigator
  • Treatment with systemic corticosteroid or other systemic therapies given for at least 3 months within the previous 12 months prior to Day 1
  • The degree of inflammation with anterior chamber cells ≥ Grade 1 and/or vitreous haze of ≥ Grade 1 and/or evidence of macular oedema in the study eye considered to be caused by recurrent uveitis
  • Visual acuity of study eye is at least 35 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart
  • No evidence of medically unstable systemic disease defined as any systemic disease requiring a change (increase or decrease) in systemic treatment in the 90 days prior to Day 1
  • Ability and willingness to comply with the treatment and follow-up procedures
  • No expectation that the subject will be moving out of the area of the clinical centre to an area not covered by another clinical centre during the next 36 months

Who cannot take part

  • Toxoplasmosis scar in study eye; or scar related to previous viral retinitis
  • Previous viral retinitis
  • Prior administration of intravitreal Ozurdex within 6 months of the screening visit
  • Prior administration of fluocinolone intravitreal implant within 3 years of the screening visit in the study eye
  • Capsulotomy in study eye within 30 days prior to Day 1
  • History of certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any malignancy receiving treatment, or in remission less than 5 years prior to Day 1
  • Systemic infection within 30 days prior to Day 1
  • History of any form of glaucoma or ocular hypertension in study eye, unless study eye has been previously treated with an incisional IOPlowering surgical procedure at least 90 days prior to the screening visit and that procedure has resulted in stable IOP in the normal range (10- 21 mmHg))
  • Treatment with an investigational drug or device within 3 months prior to Day 1
  • Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the End of Study (Month 36)
  • Increased intraocular pressure >25 mmHg or that required treatment including increases in medications, surgery (other than drainage surgery), or hospitalisations, within 4 weeks prior to baseline that, in the opinion of the Investigator, would pose an unacceptable risk to the patient participating in the study
  • History of intraocular surgery in the study eye within 90 days of the screening visit
  • Vitreous haemorrhage
  • Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma)
  • Ocular malignancy in either eye, including choroidal melanoma
  • Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and mycobacterial infections of the eye or fungal diseases of ocular structure
  • Hypersensitivity to FA or any component of ILUVIEN
  • Ocular or adnexal infections or infectious uveitis in the study eye
  • Subjects requiring chronic systemic or inhaled corticosteroid therapy (>0.15 mg/kg daily) or systemic immunosuppressive therapy for autoimmune conditions other than Juvenile Idiopathic Arthritis, Blau syndrome, Idiopathic Chronic Anterior Uveitis, Intermediate Uveitis, Idiopathic Panuveitis
  • Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the Investigator, could make the subject inappropriate for entry into this study
  • Any other systemic or ocular condition which, in the judgment of the Investigator, could make the subject inappropriate for entry into this study
  • History of posterior uveitis only that was not accompanied by vitritis or macular oedema
  • History of iritis only and no vitreous cells, anterior chamber cells (ACC), or vitreous haze
  • Media opacity precluding evaluation of retina and vitreous
  • Peripheral retinal detachment and/or vitreoretinal traction in area of area of insertion
  • Viral corneal pathology in the study eye
  • Moderate to severe dry eye in the study eye
  • Chronic hypotony (< 6 mmHg)
  • Any persons with a dependent relationship to the sponsor, the investigational site or the Investigator
  • Any persons held in an institution by a government or judicial order
  • Best corrected visual acuity (BCVA) < 20/200 in the study eye at screening and Day 1
  • Uveitis with infectious aetiology
  • Mycobacterial uveitis or chorioretinal changes of either eye which, in the opinion of the Investigator, resulted from infectious mycobacterial uveitis

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in Germany and Spain.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate safety and efficacy of ILUVIEN® 190μg in paediatric subjects with recurrent non-infectious uveitis affecting the posterior segment of the eye

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A non-randomised, open-label, uncontrolled, multi-centre, phase IIIb study evaluating the safety and efficacy of fluocinolone acetonide 190 micrograms intravitreal implant in paediatric subjects from 6 years to less than 18 years with recurrent non-infectious uveitis affecting the posterior segment of the eye.
Plain-language title
ILUVIEN eye implant for children with recurring uveitis at the back of the eyeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from 2023-509469-19-00, who can take part
Record updated
30 April 2026